NCT00513279View on ClinicalTrials.gov

To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 28, 2007

Primary Completion Date

October 4, 2007

Study Completion Date

October 4, 2007

Conditions
Substance Dependence
Interventions
DRUG

GSK618334

GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.

DRUG

GSK618334 matching placebo tablets

GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.

Trial Locations (1)

HA13UJ

GSK Investigational Site, Harrow

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00513279 - To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334 | Biotech Hunter | Biotech Hunter